Sponsors

The organisations below are sponsor of BCF Career Event 2019. Would you also like to become a sponsor? Please contact Laura Hillege via l.hillege[at]hyphenprojects.nl or +31(0)35 303 0013.

MAIN SPONSORS 2019

Johnson & Johnson

JANSSEN: PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON
'With over a 100 year of experience the Johnson & Johnson “family of companies” focuses on the medical, consumer and pharmaceutical market with a strong focus on research based and technology driven products. Johnson & Johnson strives to make a difference in healthcare. Johnson & Johnson is the mother company of a.o. Janssen (before Crucell, Janssen Biologics) which will all be present on the career fair. Take a look at the website of Johnson & Johnson for more information.'

CLS Services

CLS Services
'Through our vast experience with clients we have built expert knowledge within the Chemistry and Life Sciences domain when it comes to recruitment & selection and career coaching. We work as a team. We share ideas, knowledge and skills with each other, in order to achieve excellent results. With the purpose that our clients profit from the expert knowledge of our employees. Only through really understanding the needs and challenges of our candidates and our clients, we can help people and organisations to achieve lasting good results. Interested to know what we can do for you? Visit our website www.cls-services.nl. For current vacancies see all available here or send an open application.'

SPONSOR 2019

QTC Recruitment

QTC Recruitment
Info will follow soon.

Genmab

Genmab
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications and solid tumors. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies.

Our sponsors
Login